Subscribe to Newsletter
Business & Regulation Business Practice, Standards & Regulation, Trends & Forecasts

An Issue of Quality

Any pharma company in any country can fall afoul of regulators, but 2015 has seen a number of warning letters and export bans targeting Indian facilities, leading the Associated Chambers of Commerce & Industry of India (ASSOCHAM) to admit that the country is feeling the strain, particularly when it comes to conducting inspections. ASSOCHAM is now calling on India’s pharma industry to do more to ensure that it doesn’t fall behind. At the moment, India ranks fourth in the world in pharmaceutical production, but ASSOCHAM expects a significant amount of drug export revenue to take a setback during the fiscal year 2013-14 because of recent difficulties (1).

“India has a meager number of 1,500 well equipped inspectors for more than 10,000 factories engaged in pharmaceutical products leading to the country’s products facing regulatory hurdles in the overseas markets,” explained an ASSOCHAM statement. “The mismatch between the domestic regulatory mechanism and the international regime is resulting in recall and rejection of drugs made by even some of the well known companies, leading to unrest and frustration.”

Some of the most high-profile incidents to have plagued India’s pharma industry recently include: the European Medicines Agency banning around 700 generic medicines tested by GVK BioSciences and an FDA warning letter for three Dr Reddy’s plants in November 2015.

According to ASSOCHAM, India faces a number of challenges when it comes to exporting to heavily regulated markets like Europe and the US, particularly as there is no global harmonization of quality systems. There are also domestic challenges related to accessing finance; Indian companies can receive subsidies from the Indian government to help carry out quality checks – but only if they are located in certain areas within the country.

ASSOCHAM says, “While at times, the FDA gets into minute details which have more to do with the cumbersome procedure rather than quality, we need to get our own house in order by way of continuous skilling of the regulators at the national and state levels in sync with the best global practices.”

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. The Associated Chambers of Commerce & Industry of India, “Severe shortage of well equipped drug inspectors hurting pharma exports: ASSOCHAM study,” (December, 2015). www.assocham.org
About the Author
Stephanie Vine

Making great scientific magazines isn’t just about delivering knowledge and high quality content; it’s also about packaging these in the right words to ensure that someone is truly inspired by a topic. My passion is ensuring that our authors’ expertise is presented as a seamless and enjoyable reading experience, whether in print, in digital or on social media. I’ve spent fourteen years writing and editing features for scientific and manufacturing publications, and in making this content engaging and accessible without sacrificing its scientific integrity. There is nothing better than a magazine with great content that feels great to read.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register